Drug Profile
CTL 8004
Alternative Names: CTL-8004Latest Information Update: 11 Oct 2006
Price :
$50
*
At a glance
- Originator Dendreon Corporation; Johnson & Johnson Pharmaceutical Research & Development
- Class
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Jul 2002 Phase-I clinical trials in Cancer in USA(unspecified route)
- 17 Oct 2000 New profile
- 17 Oct 2000 Preclinical development for Cancer in USA (Unknown route)